We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Presenilin Mutations Linked to Age of Onset in Alzheimer's

By Biotechdaily staff writers
Posted on 08 Dec 2003
Researchers studying the genetics of Alzheimer's disease (AD) have found a presenilin gene mutation associated with variable age of onset AD (from 35 to 85 years old) in one family and two presenilin gene mutations associated with early onset AD (from 49 to 54 years old) in two other unrelated families.

Familial Alzheimer disease (FAD) accounts for approximately 5-10% of all cases of AD. More...
This disorder is genetically heterogeneous and can be categorized according to age-of-onset using 60 years as a cut-off. The early-onset FAD genes include the amyloid protein precursor (APP) gene on chromosome 21, the presenilin 1 (PS1) gene on chromosome 14, and the presenilin 2 (PS2) gene on chromosome 1. Approximately 50% of early-onset FAD is accounted for by defects in these genes, with the majority occurring in the PS1 gene.

Investigators at the University of Florence (Italy; www.unifi.it) used polymerase chain reaction (PCR) single-strand conformation polymorphism and DNA sequencing to analyze samples from 45 individuals from Italian families with members suffering from FAD.

They report in the November 2003 issue of the Archives of Neurology that they had found one novel PS2 mutation associated with highly penetrant but variable age at onset (35-85 years) and two novel PS1 missense mutations associated with early-onset Alzheimer disease at age 49 to 54 years.

The authors stated, "Results of this study confirm and extend the concept that the clinical manifestation of PS1 and PS2 mutations may be typical for AD and more similar to other dementias. In addition, the identification of new mutations is important, particularly for developing diagnostic testing programs based on the frequency of mutations in specific populations and for further enlarging out understanding of the great variability of FAD.”



Related Links:
University of Florence

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.